Senores Pharmaceuticals Limited – IPO

The Senores Pharmaceuticals IPO is structured as a book-built issue. It consists of a fresh issue amounting to Rs 50.00 crore and an offer for sale of 0.21 crore shares.

The subscription for the Senores Pharmaceuticals IPO is scheduled to open on December 20, 2024, and will close on December 24, 2024. The allotment of shares is expected to be finalized on Thursday, December 26, 2024. The IPO is planned to be listed on BSE and NSE, with the tentative listing date set for Monday, December 30, 2024.

The price bands for the Senores Pharmaceuticals IPO have not yet been announced.

Get the Senores Pharmaceuticals IPO RHP for detailed information.

Senores Pharmaceuticals Limited – IPO Details

IPO Date December 20, 2024 to December 24, 2024
Listing Date December 30, 2024
Face Value ₹ 10 / Share
Price Band ₹ 372 to ₹ 391 / Share
Lot Size 38 Shares
Total Issue Size ₹582.11 Cr
Fresh Issue ₹ 500.00Cr
Offer for Sale 21,00,000
Employee Discount
Issue Type Book Built Issue IPO
Listing At BSE, NSE
Share holding pre issue 3,32,65,865
Share holding post issue 4,60,53,588
Market Maker portion

Senores Pharmaceuticals Limited Timeline (Tentative Schedule)

Senores Pharmaceuticals Limited IPO opens on December 20, 2024, and closes on December 24, 2024.

IPO Open Date December 20, 2024
IPO Close Date December 24, 2024
Basis of Allotment December 26, 2024
Initiation of Refunds December 27, 2024
Credit of Shares to Demat December 27, 2024
Listing Date December 30, 2024
Cut-off time for UPI mandate confirmation December 24, 2024

Senores Pharmaceuticals Limited IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 38 Rs.14,858
Retail (Max) 13 494 Rs.193,154
S-HNI (Min) 14 532 Rs.208,012
S-HNI (Max) 67 2,546 Rs.995,486
B-HNI (Min) 68 2,584 Rs.1,010,344
HNI (Min)

Senores Pharmaceuticals Limited IPO Promoter Holding

Share Holding Pre Issue 71.10%
Share Holding Post Issue

Senores Pharmaceuticals Limited IPO Reservation

Investor Category Shares Offered Maximum Allottees
Anchor Investor Shares Offered
Market Maker Shares Offered
Other Shares Offered
QIB Shares Offered Not less than 75% of the Net Issue
NII (HNI) Shares Offered Not more than 15% of the Net Isssue
bNII > ₹10L
sNII < ₹10L
Retail Shares Offered Not more than 10% of the Net Issue
Employee Shares Offered
Total Shares Offered

Senores Pharmaceuticals Limited IPO Anchor Investors Details

Bid Date 2024-12-19
Shares Offered
Anchor Portion Size (In Cr.) 260.63
Anchor lock-in period end date for 50% shares (30 Days) January 25, 2025
Anchor lock-in period end date for remaining shares (90 Days) March 26, 2025

About Senores Pharmaceuticals Limited

Incorporated in December 2017, Senores Pharmaceuticals Limited is engaged in the development and manufacturing of a range of pharmaceutical products, primarily targeting the regulated markets of the US, Canada, and the UK, while also catering to emerging markets.

The company's product portfolio includes Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets, Topiramate Capsules, and Ivermectin Tablets for regulated markets.

As of September 30, 2024, 55 products have been launched by the company in key therapeutic areas, including antibiotics and anti-fungal treatments. Partnerships have been established with distributors and hospitals across several states in India.

The company operates three dedicated R&D facilities in India and the US as of September 30, 2024.

Operations have expanded into emerging markets across 43 countries, with critical care injectables and APIs being manufactured.

The company's manufacturing unit is located in Ahmedabad, Gujarat.

Key Performance Indicator

KPI Values
ROE 23.60%
ROCE 11.73%
Debt/Equity 1.07
RoNW 23.60%
P/BV
PAT Margin (%) 15.25
  Pre IPO Post IPO
EPS (Rs) 9.83 13.86
P/E (x) 39.77 28.21

Objects of the Issue (Senores Pharmaceuticals Limited IPO Objectives)

The Net Proceeds are proposed to be utilized by the Company for the following objectives:

  • An investment is planned in one of its subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for establishing a manufacturing facility for sterile injections at the Atlanta Facility.
  • Certain borrowings availed by the Company are to be repaid or pre-paid, either in full or in part.
  • An investment will be made in the subsidiary, Havix, for the repayment or pre-payment, in whole or in part, of certain borrowings availed by the subsidiary.
  • The Company’s working capital requirements are to be funded.
  • Investments are planned in the subsidiaries, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to support their working capital requirements.
  • Inorganic growth will be supported through acquisitions and other strategic initiatives, along with general corporate purposes.

Senores Pharmaceuticals Limited Contact Details

Senores Pharmaceuticals Limited

1101 to 1103, 11th floor,

South Tower, ONE 42 oppositeJayantilal Park,

Ambali Bopal Road, Ahmedabad,-380054

Phone: +91-79-29999857

Email: cs@senorespharma.com

Website: https://senorespharma.com/

Senores Pharmaceuticals Limited IPO Registrar

Link Intime India Private Ltd

Phone: +91-22-4918 6270

Email: senorespharma.ipo@linkintime.co.in

Website: https://linkintime.co.in/Initial_Offer/public-issues.html

Frequently Asked Questions


What is Senores Pharmaceuticals Limited IPO?
The Senores Pharmaceuticals Limited IPO is classified as an Mainline IPO. The issue price is set between ₹372 and ₹391 per equity share. A minimum of 38 shares is required per order. The IPO will be open from December 20, 2024, to December 24, 2024. The shares are proposed to be listed on BSE, NSE.

When does the Senores Pharmaceuticals Limited IPO open and close?
The Senores Pharmaceuticals Limited IPO will be opened on December 20, 2024, and closed on December 24, 2024.

What is the issue size of the Senores Pharmaceuticals Limited IPO?
The size of the Senores Pharmaceuticals Limited IPO is in total. A fresh issue of ₹ 500.00Cr shares, aggregating up to , is included.

What is the price band of the Senores Pharmaceuticals Limited Limited IPO?
The price band for the IPO has been set between ₹372 - ₹391 per equity share.

What is the allotment date of the Senores Pharmaceuticals Limited IPO?
The share allotment date for the Senores Pharmaceuticals Limited IPO is set for December 26, 2024.

What is the Senores Pharmaceuticals Limited listing date?
The Senores Pharmaceuticals Limited IPO is scheduled to be listed on December 30, 2024.

Lamfindia specializes in offering innovative financial solutions, including stock broker services, mutual fund investments, and IPO guidance.